WRBYWarby Parker Inc.
Ophthalmic Goods
- Revenue
- $872M
- 13% YoY
- Operating margin
- -0.6%
- 84% YoY
- EBITDA
- $45M
- 185% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear68× net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $541M | $598M | $670M | $771M | $872M | 13% |
| Operating income | −$144M | −$111M | −$72M | −$30M | −$5M | 82% |
| Net income | −$144M | −$110M | −$63M | −$20M | $2M | 108% |
| Operating cash flow | −$32M | $10M | $61M | $99M | $111M | 12% |
| Capex | $49M | $60M | $54M | $64M | $67M | 4.7% |
| Stock-based comp | $107M | $98M | $71M | $47M | $35M | 27% |
| Buybacks | $8M | $0 | $0 | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 3
- Net
- −$4M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 40 | 107 |
| FY2024 | — | — | 44 | 94 |
| FY2023 | — | — | 26 | 96 |
| FY2022 | — | — | 25 | 84 |
| FY2021 | — | — | 85 | 111 |